David H. Wesorick, MD; Vineet Chopra, MD, MSc
Disclosures: Dr. Chopra reports grants from the Agency for Healthcare Research and Quality. Dr. Wesorick has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-1400.
The authors conclude that readmissions occurring within 7 days of discharge are more likely to be attributable to care provided in the hospital than readmissions occurring from 8 to 30 days, which appear more attributable to outpatient care.
The authors suggest that a 7-day readmission cutoff might be a more reasonable accountability measure for hospitals than the established 30-day cutoff. However, they also acknowledge that no cutoff will perfectly distinguish the accountability for readmissions between inpatient and outpatient care. Instead, they call for a better model of collaboration between inpatient and outpatient providers and shared accountability for readmissions.
This study shows that it is possible to utilize information about opioid prescribing patterns (e.g., information from prescription drug monitoring programs [PDMPs]) to identify patients who are at high risk for opioid-related complications.
Almost all of the studied misuse patterns (even ones that might be beneath the conventional thresholds for suspicious use) were associated with an increased risk for opioid overdose.
An accompanying editorial notes that current PDMPs are limited by a lack of standardization and a failure to present complex data in a way that is useful to clinicians (i.e., in a way that allows clinicians to easily recognize the high-risk patterns). The authors suggest that approaches aimed at these factors may lead to improvements in PDMPs and better stewardship of these medications.
Circulating Aβ40 seems to accurately predict mortality in patients presenting with NSTE-ACS, and the clinical use of this test may ultimately allow for improved risk stratification of these patients.
The authors note that, although this test may not yet be ready for clinical application, prospective studies evaluating the use of this biomarker in patients with NSTE-ACS seem necessary.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Wesorick DH, Chopra V. Annals for Hospitalists - 19 June 2018. Ann Intern Med. 2018;168:HO1. doi: https://doi.org/10.7326/AFHO201806190
Download citation file:
Published: Ann Intern Med. 2018;168(12):HO1.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use